key: cord-0767852-wwhggele authors: Abdel-Bakky, Mohamed S.; Amin, Elham; Faris, Tarek M.; Abdellatif, Ahmed A.H. title: Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic date: 2021-10-08 journal: Mol Med Rep DOI: 10.3892/mmr.2021.12479 sha: 97d9d44a4e6c562c7ed337ab1d3fd66e6a863a16 doc_id: 767852 cord_uid: wwhggele The present study aimed to review major depression, including its types, epidemiology, association with different diseases status and treatments, as well as its correlation with the current COVID-19 pandemic. Mental depression is a common disorder that affects most individuals at one time or another. During depression, there are changes in mood and behavior, accompanied by feelings of defeat, hopelessness, or even suicidal thoughts. Depression has a direct or indirect relation with a number of other diseases including Alzheimer's disease, stroke, epilepsy, diabetes, cardiovascular disease and cancer. In addition, antidepressant drugs have several side effects including sedation, increased weight, indigestion, sexual dysfunction, or a decrease in blood pressure. Stopping medication may cause a relapse of the symptoms of depression and pose a risk of attempted suicide. The pandemic of COVID-19 has affected the mental health of individuals, including patients, individuals contacting patients and medical staff with a number of mental disorders that may adversely affect the immune ability of their bodies. Some of the drugs currently included in the protocols for treating COVID-19 may negatively affect the mental health of patients. Evidence accumulated over the years indicates that serotonin (5HT) deficiencies and norepinephrine (NE) in the brain can lead to mental depression. Drugs that increase levels of NE and 5HT are commonly used in the treatment of depression. The common reason for mood disorders, including mania and bipolar disease are not clearly understood. It is assumed that hyperactivity in specific parts of the brain and excessive activity of neurotransmitters may be involved. Early diagnosis and developing new treatment strategies are essential for the prevention of the severe consequences of depression. In addition, extensive research should be directed towards the investigation of the mental health disturbances occurring during and/or after COVID-19 infection. This may lead to the incorporation of a suitable antidepressant into the current treatment protocols. brain can lead to mental depression. drugs that increase levels of ne and 5HT are commonly used in the treatment of depression. The common reason for mood disorders, including mania and bipolar disease are not clearly understood. it is assumed that hyperactivity in specific parts of the brain and excessive activity of neurotransmitters may be involved. early diagnosis and developing new treatment strategies are essential for the prevention of the severe consequences of depression. in addition, extensive research should be directed towards the investigation of the mental health disturbances occurring during and/or after coVid-19 infection. This may lead to the incorporation of a suitable antidepressant into the current treatment protocols. 1. introduction 2. epidemiology 3. Biological markers and clinical presentation of depression 4. depression and common medical diseases 5. depression and the metabolic diseases 6. depression and endocrine disorders 7. depression and cardiovascular diseases 8. Depression and inflammatory status 9. depression and daylight 10. Depression in the deficiency state 11. depression and glutamate 12. depression in neurodegenerative cases 13 . depression and oxidative stress 14. Gene expression in depression 15 . Treatment of depression 16. coVid-19 and depression 17. depression and cytokine storm in coVid- 19 18. Summary Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review) 1 Mental depression is a common psychiatric disorder, where ~264 million individuals of different ages suffered from depressive behavior at January 2020 with ~800,000 annual suicides (World Health organization, WHo) (1) . although depression has been extensively studied, its mechanisms remain to be elucidated. norepinephrine and serotonin are two neurotransmitters considered to be the most efficient in mental depression (2) . The areas in the brain supposed to be affected include the temporal and frontal lobes and the cingulate gyrus of the limbic system ( Fig. 1) (3). The symptoms of depression are mostly mild and unpredicted either by patients or even physicians. The typical types of depression, whether major or minor, have only symptoms of depression (4) . However, bipolar and cyclothymic types are accompanied by manic symptoms (5) . according to the american Psychiatric associations of the diagnostic and Statistical Manual of Mental disorders (dSM-5), depressive disorders are classified into three common types based on a theoretical basis; the first type usually occurs due to stressful stimuli. The second type is genetically based and termed endogenous depression; it is demonstrated through patient difficulties in dealing with normal life (6) . The third type is bipolar depression (or manicdepressive disorder). By contrast, the international alliance on Mental Illness classifies depression into nine common types; Major depression: patients with this type feel excessive sadness, lack of energy, irritability, hopelessness, physical pain, lower concentration, alterations in eating or sleep habits, feelings of guilt and attempted suicide. only two weeks of suffering these symptoms are needed to officially diagnose major depression (7) . dysthymia is a type of depression that causes persistent low mood with changes in sleep habits, sadness, trouble in concentration, fatigue and appetite loss. Talk therapy, not medication, is usually suitable for this type of depression (8) . Postpartum depression (PPd) usually happens after birth where the patient typically suffers from loneliness, hopelessness, deep sadness, fatigue, fear about baby disconnection and fears about harming her newborn (9) . Seasonal affective disorder generally occurs in winter, probably due to a shortage of sunlight. Symptoms are generally mild to severe. This type usually lasts in spring and natural or artificial light is usually the suitable treatment (10) . atypical depression is commonly associated with physical symptoms, including a sense of heaviness in the legs or arms together with being overweight and problems with social communication (11) . Psychotic depression is characterized by psychological symptoms including delusions, and auditory and visual hallucinations (12) . in Bipolar disorder, patients have a cycle of depression and mania symptoms. It is classified into bipolar i (where patients have at least one manic episode) (13); bipolar ii (where patients have hypomania as well as depression) (14) and cyclothymia, a cycle of depression followed by a cycle of mania (15) . Premenstrual dysphoric disorder occurs in females during the last 2 weeks of the menstrual cycle (16) . Situational depression is related to certain stressful situations and the symptoms are unhappiness, anxiety and perhaps major depression (17) (Fig. 2) . depression can be treated by non-drug or drug-containing therapy. none-drug treatment includes encouraging creativity, physical or alternative therapy including exposure to sunlight, St. John's Wort and acupuncture (18) . on the other hand, well-known antidepressant drugs including selective serotonin reuptake inhibitors (SSris), tricyclic antidepressants (Tcas), norepinephrine reuptake inhibitors (nris), serotonin antagonist and reuptake inhibitors (Saris) and serotonin-norepinephrine reuptake inhibitors (Snris) are used (19) . However, efforts have been made to find new antidepressants with high efficacy and faster response, fewer side effects, able the preserve sexual functions in patients, improved efficacy, rapid onset and improved safety profile. Mental health problems resulting from the coVid-19 pandemic comprise insomnia, anxiety, stress, fear and depressive behavior (20) . So far, there have been no data about the changes in cognitive functioning or emotions from the direct effects of the virus on the brain. a proportion of the world's population are in health quarantine and isolated at home and have lost their jobs, family members, relatives, colleagues, or friends. consequently, depression associated with coVid-19 can be included under a situational or emotional type of depression. according to the World Health organization (WHo), 264 million individuals worldwide suffer from major depression. almost 800,000 suicides are counted each year and it is the second leading cause of death among young individuals (21) . adolescents aged between 12 and 17 years exhibit the highest rate of major depressive episodes (11.3%) followed by young adults between 12 and 20 years old at 9.6% (22) . it has been observed that adults >50 years of age are less likely to have major depressive episodes (4.5%) (23) . The rate of moderate to severe depression increased from 23.2 to 41.1% from 2007 to 2018 (24). it is noted that the prevalence of depression among women is almost twice as high as that of men (25) . despite the availability of effective antidepressants with multiple mechanisms of action, it has been observed that between 76 and 85% of individuals who belong to developing countries do not receive any treatment for depression (25, 26) . There are no specific biological markers for depression. Various medical and psychiatric disorders, as well as certain drugs, have been noted in patients with depressive illness (Table i) (27) . in all, 25% of patients with a chronic medical history, including cancer, diabetes, or cardiovascular diseases, develop depressive disorder without a clear and accurate diagnosis for depression (28) . according to the dSM-5, the symptoms of major depression are sadness, anxiety or irritability, feelings of guilt and suicidal thoughts (29) . The clinical presentation could be classified into emotional and physical symptoms. Emotional symptoms include stress, sadness, anxiety, or feeling guilty, whereas physical symptoms may include sleep disturbance, appetite changes, headache, pain, or fatigue (Table ii) . depression can cause several medical diseases, including alzheimer's (by 2.0-fold) (30), cardiovascular diseases (1.5-2.0-fold) (31), stroke (1.8-fold) (31), epilepsy (4.0-6.0-fold) (32), diabetes (1.6-fold) (33) and cancer (1.3-1.8-fold) (34) (Fig. 3) . drugs used in controlling depressive illness have multiple unwanted effects, including increased weight, sedation, sexual dysfunction, indigestion, or decreased blood pressure. incompliance or stopping medication may cause a relapse of the symptoms of depression and pose a risk of attempted suicide (35). depression is usually accompanied by metabolic syndrome, obesity and type-2 diabetes (36, 37) . in diabetes, ~20.9% of males and 27% of females exhibit major depression in western Kenya (38) . By contrast, depression may increase the risk for diabetes (33) . Gastrointestinal hormones, including ghrelin, leptin and the lipid endocannabinoid, may regulate mood in the case of depression (39) . improving the depression symptoms has been accompanied by inhibition of cholecystokinin receptors in mice and also inhibits the hyperactivity of the hypothalamic-pituitary-adrenal axis (40) . neuroendocrine, noradrenergic and serotonergic are controlled by the galanin neuropeptide systems in depression and anxiety-related behaviors (41) . Furthermore, hippocampal neurogenesis is induced by an insulin-like growth factor (iGF) and the disturbance of neuronal iGF results in depression (42) . regulation of synaptic plasticity and improving depressive behavior results from releasing gastrinreleasing peptide in the hippocampus (43) (Fig. 4 ). cushing's syndrome and hypothyroidism are accompanied by a high rate of psychiatric morbidity (44) . Secondary hypothyroidism is normally characterized by decreased blood level thyroid-stimulating hormone, which is concomitant with an increased risk of depressive episodes (45) . it is found that 40% of patients with hypothyroidism suffer from clinical depression (46, 47) . Hyperthyroidism patients have a high risk of depression by 28% compared with normal individuals, whereas it occurs in 50% of all cases of patients with hypothyroidism (46, 48) . Blood and cerebrospinal levels of T4 are relatively increased during the depression (46) (Fig. 5) . The raised concentration of corticotropin-releasing factor in cerebrospinal fluid in patients with depression is noted in a previous study (49) . decreased plasma volume and elevation in blood viscosity lead to a higher risk of depression (50, 51) . Patients with depression have a high risk for hypertension, congestive heart failure and myocardial infarction (52) . Hypercoagulability, platelet activation and d-dimer proteins can be detected in patients with depression (50,53,54). in clinical trials, the risk of depression is significantly reduced in cardiovascular disease patients treated with statins (50, 55) . it has been demonstrated that vascular endothelial growth factor has neurogenic/neuroprotective effects (50, 56, 57) . Furthermore, its level is notably increased in patients diagnosed with depression (58,59). depression increases cytokines, il-6, TnF-α and il-1 (60). Furthermore, stress regulates prostaglandin-e2, lipid peroxidation il-1β, cyclooxygenase-2 and Toll-like receptor-4 ( Fig. 6 ). a previous study demonstrates that celecoxib can be used as a new strategy for major depression, especially bipolar disorder (61, 62) . in addition, nery et al (63) describe the antidepressant action of celecoxib, which is characterized by its rapid-onset antidepressant activities. Sesamol, a potent antioxidant and cytokine inhibitor, has been shown to improve chronic stress-induced depression in an experimental mouse model (64). Deficiency of light has been shown to suppress neurogenesis and increase symptoms of depression (65) . nocturnal melatonin, vitamin d and platelet 5-HT values are induced by environmental light and improve depression symptoms (66, 67) . Melatonin has anti-oxidative effects, increases sleep propensity and has been known to decrease alertness and attenuate weight gain (68) (Fig. 7 ). Intake of omega-3 fatty acids, fish, vitamin B6, vegetables, fruits, folate, olive oil, vitamin B12, nuts and legumes improves depressive symptoms although the exact mechanism remains to be elucidated (69, 70) . a previous study demonstrates that unipolar depression can be effectively controlled by folic acid (71) . a study conducted on >70 patients showed that major depressive disorder in non-responders to SSris could be improved by s-adenosyl methionine if taken concurrently with serotonin reuptake inhibitor (72) (Fig. 8 ). The ionotropic glutamate receptors n-methyl-d-aspartate (nMda), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and metabotropic glutamate receptors (mGlur1 to mGlur8) activation regulate synaptic plasticity and transmission. Glutamate is cleaned by high-affinity excitatory amino acid transporters (eaaT) 1 and 2 from extracellular space found in glial cells (73) . Following the conversion of the glial cells glutamate to glutamine, by glutamine synthetase, glutamine is hydrolyzed into glutamate via glutaminase (74) . in experimental animal models of depression, drugs that increase glutamate clearance can improve stress and possess antidepressant effects (75, 76) . Ketamine n-methyl-d-aspartate receptor antagonist in subanesthetic dose (0.5 mg/kg) has a short onset antidepressant effect (77). another rapid-acting antidepressant is dextromethorphan (nMda receptor antagonist) (78). The antimuscarinic drug scopolamine has short onset with a potent antidepressant effect for bipolar and major depression (79, 80) . as with nMda receptor antagonists, zinc and magnesium have an antidepressant effect in experimental animal models (81) . it has been stated that magnesium has an antidepressant effect in type ii diabetic patients, compared with imipramine (82). long-time stress may negatively affect the process of neurogenesis and cause neuronal loss in the hippocampus (83, 84) . in depressive behaviors, synaptic plasticity has been revealed to be controlled by brain-derived neurotrophic factor (BdnF) (85, 86) . The blood level of BdnF is decreased in patients with depression and its level is increased by antidepressant drugs (87, 88) . in patients with depression, a decreased level of vascular growth factor (VGF) has been shown (89) and an antidepressant effect is produced by treatment with recombinant VGF in an experimental animal model (90) . neurotrophin-3 and nerve growth factor may contribute to the antidepressant responses by improving plasticity and neurogenesis in the hippocampus (91, 92) . other factors such as glial cell linederived neurotrophic factor and fibroblast growth factor-2 are modulated in depression (58, 93) (Fig. 9 ). in patients with depression, numerous enzyme-mediated reactive oxygen species (roS) production is increased (94) . Superoxide and hydrogen peroxide are products of oxidation of xanthine mediated by xanthine oxidase enzyme that has been Figure 5 . depression and endocrine disorders. cushing's syndrome and hypothyroidism are accompanied by a high rate of psychiatric morbidity. The raised concentration of thyrotrophin releasing hormone in cerebrospinal fluid in patients with depression is noted in a previous study. Secondary hypothyroidism is characterized by decreased blood level thyroid-stimulating hormone, which is concomitant with an increased risk of depressive episodes. it is found that 40% of patients with hypothyroidism suffer from clinical depression. Hyperthyroidism patients have a high risk of depression by 28% compared with normal individuals, whereas it occurs in 50% of all cases of patients with hypothyroidism. Blood and cerebrospinal levels of T4 are relatively increased during the depression. T4, thyroxin; TSH, thyroid stimulating hormone. found to increase in the thalamus in postmortems of patients with depression (95) . Metabolism and oxidative deamination of serotonin are exaggerated by monoamine oxidase, which can cause roS production leading to mitochondrial dysfunction and neuronal apoptosis (96) . in addition, coX-2 is involved in the inflammatory cascades and its inhibitors can lead to neuronal inflammation that may worsen depression (97) . decreased superoxide dismutase activity is shown in patients diagnosed with depression (98) . Peroxides, such as hydrogen peroxide catalyzed by glutathione peroxidase, have lower activity in patients with depression compared to healthy individuals (99) . Microglia are the main inflammatory neuronal cells that are activated by the increased levels of superoxide and other roS (100). This activated cell releases a number of inflammatory cytokines, mostly TNF-α and il-6 (101). it has been demonstrated that an increased level of nitric oxide (no) mediates the 3',5'-cyclic guanosine monophosphate (cGMP) signaling pathway leading to depressive symptoms; however, the reduction of no and/or cGMP results in improvement in depression-like symptoms in experimental animal models (102) . The elevated level of no may react with superoxide anions and produce highly reactive inflammogenic and neurotoxic peroxynitrite and consequently a local surge in inflammatory cytokines (103) . The previous NO effects are involved in the pathogenesis of major depression (104), Parkinson's disease and alzheimer's (103). There are differences in the cortical gene expression in patients with schizophrenia, bipolar disorder and autism including differentiation of the glial cell and metabolism of fatty acid (105, 106) . notably, the pathophysiology of major depression (Md) involves inflammatory pathways and the hypothalamic-pituitary axis (107) . another study found low expression of two genes, aTP binding cassette subfamily G member 2 and prominin 1 in patients with Md (108). Similarly, a low level of mrna encoding the gene Fli-1 proto-oncogene, eTS transcription factor has been found and it serves a role in the growth of the neuronal crest in patients with depression (109) . reduction in the expression of Slc1a2 and Slc1a3 genes has been found in the dorsolateral prefrontal cortex and anterior cingulate of patients with Md and bipolar disorder (110) . a lower expression of nMda receptor subunits was found in patients with Md including PSd-95, nr1, nr2a and nr2B in the anterior prefrontal cortex (111) . GaBa signaling-related genes such as aldH9a1 and glutamate ammonia ligase, are changed in patients with depression (112) . aldH9a1, which catalyzes the conversion of γ-aminobutyraldehyde into GaBa, was increased in depressed subjects, whereas glutamate ammonia ligase, which increases glutamate brain clearance by its conversion to glutamine, was decreased in depressed brain. Furthermore, decreased activation and functions in the gene expression of the extracellular signal-regulated kinase (erK) cascade is recorded in Md (113) . Several deviations in the gene expression in MD were found to be gender-specific, occurring mostly in females. For instance, hub gene dusp6 (female-specific gene) is downregulated in female, but not male mice prefrontal cortex simulated stress by increasing pyramidal neuron excitability and erK signaling. This gender-specific feature in MD patients could be due to changes in the specificity of ventromedial cortex content of phosphatase 6 in female patients and empty spiracles homeobox 1 in males (113) . None drug treatment Encouraging creativity. reading books or journals, gardening, painting and playing music can offer a passage to drive out the painful thoughts and bad moods. it is known that creative individuals are at high risk for depression than non-creative ones (114) . Figure 9 . depression and neurodegenerative cases. long-time stress may negatively affect the process of neurogenesis and cause neuronal loss in the hippocampus. in depressive behaviors, synaptic plasticity has been revealed to be controlled by BdnF. The blood level of BdnF is decreased in patients with depression and its level is increased by antidepressant drugs. in patients with depression, a decreased level of VGF has been shown and an antidepressant effect is produced by treatment with recombinant VGF in an experimental animal model. nT-3 and nGF may contribute to the antidepressant responses by improving plasticity and neurogenesis in the hippocampus. other factors, such as GdnF and FGF-2, are modulated in depression. BdnF, brain-derived neurotrophic factor; VGF, vascular growth factor; nT-3, neurotrophin-3; nGF, nerve growth factor; GdnF, glial cell line-derived neurotrophic factor; FGF-2, fibroblast growth factor-2. Figure 8 . Depression and deficiency. Intake of omega-3 fatty acids, fish, vitamin B6, vegetables, fruits, folate, olive oil, vitamin B12, nuts and legumes improves depressive symptoms, although the exact mechanism remains to be elucidated. a previous study demonstrates that unipolar depression can be effectively controlled by folic acid. a study conducted on >70 patients showed that major depressive disorder in non-responders to selective serotonin reuptake inhibitors could be improved by s-adenosyl methionine if taken concurrently with serotonin reuptake inhibitor. Physical therapy. in this, patients with depression are directed to perform physical exercise. The only challenge facing this strategy is that patients with depression often suffer from a lack of energy. However, starting a new physical activity can be influential in managing such symptoms. Performing physical exercise is known to produce euphoria by releasing endorphins (115) . Psychiatric therapy. cognitive Behavioral Therapy is a common psychotherapy strategy used in the treatment of depression. This strategy directs patients to correct negative non-constructive thinking (116) . Alternative therapy. a 40 min exposure to sunlight by patients suffering from seasonal depression results in a good response (117) . This type of therapy may be helpful in patients suffering from seasonal depression. St. John's Wort and acupuncture are used and can improve depressive behavioral symptoms (118) . Other antidepressants LY03005 (Ansofaxine hydrochloride). ansofaxine is developed by luye Pharma Group for the treatment of major depression. The american food and drug administration (Fda) approved the serotonin-norepinephrine-dopamine triple reuptake inhibitor lY03005 in december 2020 under the name of ansofaxine (121). it was developed under luye pharma's new chemical and therapeutic entities research and development platform (122) . Triple reuptake inhibitors encourage a class of antidepressants and are considered to have high efficacy and faster antidepressant response. They have relative advantages in preserving patients' sexual functions, improved efficacy, rapid onset and improved safety profile (122) . Duloxetine. duloxetine hydrochloride (cymbalta) is an oral selective serotonin and norepinephrine reuptake inhibitor. it has been accepted in the treatment of different mental disorders, including depressive behavioral illness (123) . one important benefit that leads to the use of duloxetine in the treatment of depression is its effect in the prevention of suicidal thoughts and attempts (124) . Wu et al (125) demonstrate that duloxetine may be effective in the treatment of epileptic patients with depression. a recent study demonstrated that a spray-dried complexationbased transdermal patch of duloxetine functions as a possible new drug delivery system in the treatment of depression (126) . Vilazodone (Viibryd). Vilazodone was approved by the Fda in January 2011 and it is the first and only selective serotonin reuptake inhibitor and 5-HT1a receptor partial agonist (127) . a large dose of vilazodone is accompanied by acute serotonin syndrome. Some serious uncommon adverse effects include suicidal thoughts, sexual dysfunction, manic behavior, serotonin syndrome and hyponatremia (128) . GLYX-13 (Rapastinel). GLYX-13 finalized phase II in 2015 and on January 29, 2016 allergan company reported that rapastinel had received approval from the Fda for treatment of major depression (129) . GlYX-13 functions by controlling the neuronal n-methyl-d-aspartate (nMda) receptor. although it is similar to ketamine receptor antagonists of nMda, GlYX-13 does not cause severe adverse effects such as schizophrenic symptoms and hallucinations effects (130) . Vortioxetine (Brintellix) . Brintellix, used for the treatment of major depression, is recently available in the united States markets (131) . The antidepressant mechanism of Brintellix remains to be elucidated. Vortioxetine is a 5-HT1d, 5-HT3 and 5-HT7 receptors antagonist, 5-HT1B partial receptors agonist and 5-HT1a receptor agonist (132) . Plasma concentration of BDNF shows a significant increase and the concentration of platelet 5-HT displays significant reduction following Brintellix administration in patients with major depression (129) . Valdoxan targets the melatonin system in the brain and is considered a melatonergic drug. it was approved for the treatment of major depression in europe in 2009. it has been recently reported that agomelatine is effective in PPd treatment and is safe during breastfeeding (133) . agomelatine works by targeting the neuronal effects of melatonin, which has an essential role as an antidepressant. Similar to serotonin, agomelatine appears to be important in controlling sleep and circadian rhythms (134, 135) . Ketamine. it is an anesthetic drug that has an antidepressant effect but is not yet accepted as an antidepressant by the Fda. Ketamine acts on a number of central nervous system receptors responsible for learning and memory. These receptors work on the excitatory neurotransmitter, glutamate (136) , which activates mTorc1 kinase via inactivation of eukaryotic initiation factor 4e-binding proteins (137) . intranasal spray of ketamine was Fda approved as an antidepressant. Finally, the safety and efficacy of ketamine in depression control requires further investigation (138) . Levomilnacipran. levomilnacipran is a rapid onset drug used for treatment of depression that belongs to a class of Snris. There is no evidence to indicate any relative advantages of levomilnacipran compared with available Snris (139) . a recent study demonstrated that levomilnacipran in older patients with depression has lower tolerability than in older adults with depression. levomilnacipran requires to be more deeply studied to analyze its efficacy and tolerability in patients with depression (140) . Quetiapine (Seroquel XR). although it inhibits nerve communication between the brain areas, like other atypical anti-psychotics, the mechanism of quetiapine remains to be elucidated. a promising result of Snri (Venlafaxine) and Quetiapine co-treatment in patients with depression has been reported (141) . The benefits of Quetiapine may be due to inhibition of the serotonin type 2 and dopamine type 2 receptors (142) . Hazards of mortality, suicidal thoughts and stroke in the elderly are common among patients treated with Quetiapine (143). The outbreak of COVID-19 seriously influences mental health. The pandemic represents a stressful situation worldwide and at the time of writing this review, the confirmed cases are >177,108,695 including 3,840,223 mortalities (WHo; https://covid19.who.int). Mental health problems resulting from this pandemic include insomnia, anxiety, depressive behavior, stress and fear (144) . in the aftermath of the coVid-19 pandemic, depression and anxiety are common psychological complaints (145) . lai et al (146) observed the mental health status during the coVid-19 pandemic in 1,257 doctors and other healthcare staff in china. it was found that 71.5% of the study sample claimed distress, 50.4% depression, 44.6% anxiety and 34.0% insomnia. in addition, a possible correlation between the symptoms in coVid-19 patients and potential neurological consequences has been found (147) . at present, nothing is known about the changes in cognitive functioning or emotions from the direct effects of the virus on the brain. a number of individuals are in health quarantine and isolated at home and have lost their jobs, family members, relatives, colleagues, or friends. accordingly, depression due to coVid-19 may be included under the situational or emotional type of depression. There are a number of drugs under investigation in different research institutes, universities, or under clinical trials in hospitals. The investigational drugs include Baricitinib, interferon-β 1b, Bemcentinib, Bevacizumab, chloroquine phosphate, colchicine, dexamethasone, eidd-2801, Favipiravir, Hydroxychloroquine, azithromycin, anticoagulants, lopinavir, ritonavir and remdesivir. The current use of some of these drugs in certain areas is marked with hopes and promises without attention being payed to their behavioral side effects and lethality. For example, Baricitinib (olumiant r which is a Janus kinase inhibitor now in phase iii clinical trials for coVid-19 treatment and has been used in the treatment of rheumatoid arthritis. olumiant may occasionally lead to depression as a side effect (148) . another drug that has been used recently in the treatment of coVid-19 is interferon-β 1b. clinical studies on the efficacy of interferon I α and interferon β in SarS-coV (149) . The most serious side effects of interferon-β-1b in clinical trials are attempted suicide, depressive behavior and necrosis at the site of injection (150). dexamethasone is a common and widely used synthetic steroid for a number of diseases, which can reduce mortality of seriously ill coVid-19 patients although with no improving effect in less serious cases (151) . Fortunately, dexamethasone level has previously been shown to possess a good prognosis for endocrine dysfunction in depression (152) . The united States Fda has approved the use of the antimalarial drugs chloroquine (n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-1,4-pentanediamine) and hydroxychloroquine sulfate (a derivative of chloroquine) in coVid-19 treatment regardless of a questionable clinical proof of their effectiveness (153). Behavioral changes, delirium and depression have been associated with chloroquine use (153). one of the most important points that must be taken into account is the older population, who are directed to self-isolate for a long time. This is to protect over-loaded health systems and to diminish the outbreak of coVid-19. This social isolation not only increases the risk for neurocognitive, cardiovascular and autoimmune diseases but also exposes elder populations to a greater risk of depression (154) . decision makers and leaders need to realize the resultant mental health changes. in addition, they must take the situational depression existing at present into their consideration and give it the care and attention it deserves. alteration in consciousness is one of coVid-19 manifestations and accounts for 20% of patients (155) . Furthermore, increased incidence of psychiatric disorders has been identified during and after the infection with COVID-19 (156) . Most of these patients display cytokine storm or cytokine release syndrome and showed raised plasma levels of pro-inflammatory cytokines including il-2r, il-6, il-8, il-10 and TnF-α (157) . Depression is known to be an inflammatory state in which the patients manifested high levels of inflammatory cytokines, normalized after anti-depressants treatment (158) . in the central nervous system and the peripheral blood, elevated levels of il-1β, il-6, il-8, crP and TnF-α cytokines are identified in patients with depression (159) . Blocking of cytokines by il-1β receptor antagonist, anakinra or il-6 receptor antagonist Tocilizumab (160) has benefits on the inflammation-mediated respiratory failure in patients with depression. Based on the previous reports, the present study suggested the protective effect of cytokine blockers against depression symptoms in coVid-19 patients. Treatment of depression remains a great public mental health problem. depression comprises different types, some of which are related to events in a person's life while others are related to the chemical changes in the brain. in some cases, depression may be considered as a risk factor for certain diseases (e.g. type 1 or 2 diabetes), and in other cases, certain diseases (e.g. alzheimer's and epilepsy) may lead to depressive episodes. Thus, the relationship between such diseases and depression was discussed in the present study. in addition, the newer treatments of depression, such as modulation of glutamatergic, neuronal nMda and serotonergic systems and triple reuptake inhibitors, were also presented. The newer treatments result in a lower risk of suicidal attempts compared to older treatments. However, they still have some risks including the possibility of drug abuse. cooperation between governmental organizations, researchers, clinicians, patients and family is crucial in future progress. until now, nothing has been known about the direct effect of coVid-19 on the brain. What health care staff can do is to treat depression resulting from coVid-19 infection and its complications, if there are any. The challenge facing health care staff is to treat the so-called defeat stress resulting from the consequences of coVid-19 infection. defeat stress consequences may not be able to respond to the classical antidepressants which include maladaptive behaviors (161, 162) . coVid-19 patients need both pharmacological treatment and mental care. Mental health personnel have to be close to coVid-19 patients directly or indirectly through the internet video media or telephone to soothe or prevent waves depression or low moods. Decision-makers and officials all over the world need to know that emotional or situational depression has to be taken seriously. Funding no funding was received. not applicable. MSaB conceived, designed, analyzed and presented diagrams, wrote and revised the review. aHa and ea constructed diagrams, wrote and revised the review. TMF wrote and revised the review. data authentication is not applicable. all authors read and approved the final manuscript. Ethics approval and consent to participate not applicable. not applicable. The authors declare that they have no competing interests. Yunes ra, Kovtun aS, ushakova VM, Morozova aY, Kostyuk GP, danilenko Vn and chekhonin VP: Bacterial metabolites of human gut microbiota correlating with depression role of norepinephrine in depression Brain structure alterations in depression: Psychoradiological evidence The molecular and cellular mechanisms of depression: a focus on reward circuitry Bipolar disorder: clinical overview american Psychiatric association a and association aP: diagnostic and Statistical Manual of Mental dsorders (dSM-5). american Psychiatric association assari S: chronic medical conditions and major depressive disorder: differential role of positive religious coping among african americans, caribbean blacks and non-hispanic whites devanand dP: dysthymic disorder in the elderly population obesity and mental disorders during pregnancy and postpartum: a systematic review and meta-analysis Seasonal affective disorder: is there light at the end of the tunnel? comorbid atypical depression in borderline personality disorder is common and correlated with anxiety-related psychopathology SToP-Pd Study Group: Measuring psychotic depression impact of depressive episodes on cognitive deficits in early bipolar disorder: Data from the systematic treatment optimization programme for early mania (SToP-eM) identifying early indicators in bipolar disorder: a qualitative study affective temperament and attachment in adulthood in patients with bipolar disorder and cyclothymia Premenstrual disorders and rumination Pediatric management problems. Situational depression effectiveness of complementary and self-help treatments for depression Baldwin dS: unmet needs in the pharmacological management of depression McKyer elJ, ahmed Hu and Ma P: epidemiology of mental health problems in coVid-19: a review a comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders national trends in the prevalence and treatment of depression in adolescents and young adults Trends in mood and anxiety symptoms and suicide-related outcomes among u.S. undergraduates, 2007-2018: evidence from two national surveys Kuehner c: Why is depression more common among women than among men? use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHo world mental health surveys depression and chronic medical illness diagnosis and treatment of depression in late life. consensus statement update From stress to inflammation and major depressive disorder: a social signal transduction theory of depression depression as a risk factor for alzheimer disease: The MiraGe study effect of depression on stroke morbidity and mortality Major depression is a risk factor for seizures in older adults depression and type 2 diabetes over the lifespan: a meta-analysis. response to Mezuk et al: diabetes care Wallace rB and Havlik rJ: chronically depressed mood and cancer risk in older persons optimizing outcomes in depression: Focus on antidepressant compliance depression, anxiety and glucose metabolism in the general dutch population: The new Hoorn Study eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression Symptoms of depression among patients attending a diabetes care clinic in rural western Kenya Sleep disturbances and depressed mood: a harmful combination associated with increased leptin levels in women with normal weight repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: Possible role of insulin-like growth factor 2 Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders depression and endocrine disorders: Focus on the thyroid and adrenal system Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits The relation between thyroid function and depression: a review Keane V: neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression Future prospects in depression research cSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia Mental depression and cardiovascular disease: a multifaceted, bidirectional association Stijnen T and Breteler MM: relationship between atherosclerosis and latelife depression: The rotterdam study Heartache and heartbreak-the link between depression and cardiovascular disease association between anxiety and factors of coagulation and fibrinolysis are platelets the link between depression and ischemic heart disease? am The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: Proof of concept for the inflammatory and oxidative hypotheses of depression? Vascular endothelial growth factor (VeGF) stimulates neurogenesis in vitro and in vivo VeGF is an essential mediator of the neurogenic and behavioral actions of antidepressants Gene expression and association analysis of the epithelial membrane protein 1 gene in major depressive disorder in the Japanese population dantzer r: cytokine, sickness behavior, and depression clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Bowden cl and Soares Jc: celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: Behavioral and biochemical evidences light deprivation induces depression-like behavior and suppresses neurogenesis in diurnal mongolian gerbil (Meriones unguiculatus) The influence of daylight exposure on platelet 5-HT levels in patients with major depression and schizophrenia exploring the relationship between vitamin d and basic personality traits circadian phase and its relationship to nighttime sleep in toddlers B-vitamins reduce the long-term risk of depression after stroke: The ViTaToPS-deP trial diet and the risk of unipolar depression in adults: Systematic review of cohort studies The role of nurses in the prevention and management of obesity S-adenosyl methionine (SaMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial Shea rd: roles and regulation of glutamate transporters in the central nervous system Metabolism and role of glutamate in mammalian brain Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial effect of zinc supplementation on mood states in young women: a pilot study Ba r r agá n-ro d r íg uez l, ro d r íg uez-Mor á n M a nd Guerrero-romero F: efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior Functional biomarkers of depression: diagnosis, treatment, and pathophysiology Stress, depression, and neuroplasticity: a convergence of mechanisms The neurotrophin hypothesis for synaptic plasticity The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment Salton Sr and duman rS: antidepressant actions of the exercise-regulated gene VGF Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats effects of different kinds of acute stress on nerve growth factor content in rat brain Vieta e and Kapczinski F: increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder Antioxidants as antidepressants: Fact or fiction? Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression a review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise Systems Biology of Free radicals and antioxidants. laher i Maric nP and adzic M: lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients a review on the oxidative and nitrosative stress (o&nS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness Free radicals and antioxidants-quo vadis? immune changes and neurotransmitters: Possible interactions in depression? nitric oxide and major depressive disorder: Pathophysiology and treatment implications nitric oxide signaling in brain function, dysfunction, and dementia Tobe eH: Mitochondrial dysfunction, oxidative stress, and major depressive disorder Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap B: understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and cnS studies rna-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression Stockmeier ca and Karolewicz B: reduced levels of nr2a and nr2B subunits of nMda receptor and PSd-95 in the prefrontal cortex in major depression Gene expression profiling in postmortem prefrontal cortex of major depressive disorder Sex-specific transcriptional signatures in human depression Psychotic traits in comedians intense exercise increases circulating endocannabinoid and BdnF levels in humans-possible implications for reward and depression depressive disorders in the context of biographical and historical changes-experiences within a psychiatric outpatient service The effects of sunlight exposure therapy on the improvement of depression and quality of life in post-stroke patients: a rcT study Bouron a and lorrain e: cellular and molecular effects of the antidepressant hyperforin on brain cells: review of the literature Plott SJ and nemeroff cB: neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites Bang-andersen B and Sánchez c: emerging mechanisms and treatments for depression beyond SSris and Snris Triple reuptake inhibitors as potential next-generation antidepressants: a new hope Trespidi c and Barbui c: duloxetine versus other anti-depressive agents for depression Wasiak r and Mould J: a systematic review of pharmacoeconomic studies for pregabalin anticonvulsive activity of duloxetine: a new choice for the epileptic patients with depression dahiya l and Sarwal a: Transdermal delivery of duloxetine-sulfobutylether-β-cyclodextrin complex for effective management of depression Pierz Ka and Seyfried ca: electrophysiological evidence for rapid 5-HT1a autoreceptor inhibition by vilazodone, a 5-HT1a receptor partial agonist and 5-HT reuptake inhibitor 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in indian patients with depression Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. eur arch The n-methyl-d-aspartate receptor modulator GlYX-13 enhances learning and memory, in young adult and learning impaired aging rats Vortioxetine (lu aa21004), a novel multimodal antidepressant, enhances memory in rats a randomized, doubleblind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of lu aa21004 in elderly patients with major depressive disorder Xiao l: agomelatine for postpartum depression and breastfeeding Agomelatine, the first melatonergic antidepressant: discovery, characterization and development The antidepressant agomelatine improves memory deterioration and upregulates creB and BdnF gene expression levels in unpredictable chronic mild stress (ucMS)-exposed mice Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ecT clinic antidepressant actions of ketamine engage cell-specific translation via eIF4E Ketamine and depression: a narrative review levomilnacipran: a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder cortical thickness increases with levomilnacipran treatment in a pilot randomised double-blind placebo-controlled trial in latelife depression Farmacotherapeutic treatment of psychotic depression: a review dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the Tread study a post-authorization safety study of quetiapine as antidepressant treatment in Sweden: nested case-control analyses of select outcomes The outbreak of coVid-19 coronavirus and its impact on global mental health Gunes a and ari S: anxiety and depression levels in covid-19 disease and their relation to hypertension Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019 Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib 150. reder aT, oger JF, Kappos l, o'connor P and rametta M: Shortterm and long-term safety and tolerability of interferon β-1b in multiple sclerosis dexamethasone for coVid-19? not so fast Ti me-dependent effects of dexa met hasone plasma concentrations on glucocorticoid receptor challenge tests coVid-19 and the consequences of isolating the elderly neuropsychiatric and cognitive sequelae of coVid-19 Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the coVid-19 pandemic longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SarS-coV-2 infected patients Tsamakis c, charakopoulos e, charalampous c, Spandidos da, douzenis a, Papageorgiou c, et al: depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: a case report interleukin-1 blockade with high-dose anakinra in patients with coVid-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study Efficacy and safety of tocilizumab in severe coVid-19 patients: a single-centre retrospective cohort study The role of cognitive dysfunction in the symptoms and remission from depression Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice clinical pharmacology of Mao inhibitors: Safety and future Selective serotonin reuptake inhibitor drug interactions in patients receiving statins antidepressant-induced liver injury: a review for clinicians A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression rediscovering trazodone for the treatment of major depressive disorder n-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1a agonist, as a putative mediator of quetiapine's antidepressant activity This work is licensed under a Creative Commons Attribution-NonCommercial The authors would like to thank the Deanship of Scientific research, Qassim university for their support of this project.